Prevalence of potentially relevant radiological findings with accompanying characteristics
| Radiological findings | Prevalence | Sex | Age | History of cough of any duration | History of chest pain | Bacteriological TB confirmation (Xpert/Culture) | ||
| n=1123 | %, 95% CI | Female n=721, % (95% CI) | Male n=402, % (95% CI) | Median, IQR | n=250, % (95% CI) | n=40, % (95% CI) | n=27, % (95% CI) | |
| Cardiomegaly | 259 | 23.1% (20.6% to 25.6%) | 212/721, 29.4% (26.1% to 32.9%) | 47/402, 11.7% (8.7% to 15.2%) | 59 (45–70) | 69/250, 27.6% (22.2% to 33.6%) | 9/40, 22.5% (10.8% to 38.5%) | 0/27, 0.0% (0.0% to 12.8%) |
| Cardiomegaly with heart failure | 17 | 1.5% (0.9% to 2.4%) | 12/721, 1.7% (0.9% to 2.9%) | 5/402, 1.2% (0.4% to 2.9%) | 77 (68–83) | 7/250, 2.8% (1.1% to 5.7%) | 0/40, 0.0% (0.0% to 8.8%) | 0/27, 0.0% (0.0% to 12.8%) |
| Suspected cardiac failure | 21 | 1.9% (1.2% to 2.8%) | 16/721, 2.2% (1.3% to 3.6%) | 5/402, 1.2% (0.4% to 2.9%) | 75 (67–83) | 8/250, 3.2% (1.4% to 6.2%) | 0/40, 0.0% (0.0% to 8.8%) | 0/27, 0.0% (0.0% to 12.8%) |
| Mild/moderate post-TB lung disease (Old/latent TB with=<2 lobe damage) | 85 | 7.6% (6.1% to 9.3%) | 40/721, 5.5% (4.0% to 7.5%) | 45/402,11.2% (8.3% to 14.7%) | 48 (37–66) | 18/250, 7.2% (4.3% to 11.1%) | 8/40, 20.0% (9.1% to 35.6%) | 6/27, 22.2% (8.6% to 42.3%) |
| Non-specific opacification/interstitial pattern | 52 | 4.6% (3.5% to 6.0%) | 28/721, 3.9% (2.6% to 5.6%) | 24/402, 6.0% (3.9% to 8.8%) | 59 (46–76) | 16/250, 6.4% (3.7% to 10.2%) | 1/40, 2.5% (0.1% to 13.2%) | 4/27, 14.8% (4.2% to 33.7%) |
| Active PTB | 40 | 3.6% (2.6% to 4.8%) | 15/721, 2.1% (1.2% to 3.4%) | 25/402, 6.2% (4.1% to 9.0%) | 36 (26–51) | 21/250, 8.4% (5.3% to 12.6%) | 4/40, 10.0% (2.8% to 23.7%) | 11/27, 40.7% (22.4% to 61.2%) |
| Suspected emphysema/COPD | 36 | 3.2% (2.3% to 4.4%) | 16/721, 2.2% (1.3% to 3.6%) | 20/402, 5.0% (3.1% to 7.6%) | 68 (50–73) | 11/250, 4.4% (2.2% to 7.7%) | 0/40, 0.0% (0.0% to 8.8%) | 0/27, 0.0% (0.0% to 12.8%) |
| Severe post-TB lung disease (Bronchiectasis and or destroyed lung) | 16 | 1.4% (0.8% to 2.3%) | 10/721, 1.4% (0.7% to 2.5%) | 6/402, 1.5% (0.5% to 3.2%) | 60 (34–72) | 7/250, 2.8% (1.1% to 5.7%) | 0/40, 0.0% (0.0% to 8.8%) | 2/27, 7.4% (0.9% to 24.3%) |
| Mediastinal mass (excluding goitre/TB) | 9 | 0.8% (0.4% to 1.5%) | 7/721, 1.0% (0.4% to 2.0%) | 0/402, 0.5% (0.1% to 1.8%) | 61 (56–71) | 2/250, 0.8% (0.1% to 2.9%) | 0/40, 0.0% (0.0% to 8.8%) | 0/27, 0.0% (0.0% to 12.8%) |